Impact of 10q loss, CDKN2A deletions, EGFR amplification, and trisomy of chromosome 7 in the overall survival of IDH-mutant astrocytoma
Clinical Neuropathology · 01.07.2025 · 44 (07) · 136-142
DOI: 10.5414/np301667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuropathology, erschienen am 01.07.2025. Verfasst von Mónica B Mezmezian und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Astrocytoma, Trisomy, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Mezmezian, M. B., Arakaki, N., Diez, B., Martinetto, H., & Sevlever, G. (2025). Impact of 10q loss, CDKN2A deletions, EGFR amplification, and trisomy of chromosome 7 in the overall survival of IDH-mutant astrocytoma. Clinical Neuropathology, 44(07), 136-142. https://doi.org/10.5414/np301667
Vancouver
Mezmezian MB, Arakaki N, Diez B, Martinetto H, Sevlever G. Impact of 10q loss, CDKN2A deletions, EGFR amplification, and trisomy of chromosome 7 in the overall survival of IDH-mutant astrocytoma. Clinical Neuropathology. 2025;44(07):136-142. doi:10.5414/np301667
BibTeX
@article{Mezmezian2025,
author = {Mezmezian, Mónica B and Arakaki, Naomi and Diez, Blanca and Martinetto, Horacio and Sevlever, Gustavo},
title = {Impact of 10q loss, CDKN2A deletions, EGFR amplification, and trisomy of chromosome 7 in the overall survival of IDH-mutant astrocytoma},
journal = {Clinical Neuropathology},
year = {2025},
volume = {44},
number = {07},
pages = {136--142},
doi = {10.5414/np301667}
}
EUVIMED